T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

Amplification of c-erbB2 has been reported in over 30% of uterine serous carcinoma (USC) and found to confer poor survival because of high proliferation and increased resistance to therapy. In this study, we evaluated for the first time Trastuzumab emtansine (T-DM1), a novel antibody–drug conjugate,...

Descripción completa

Detalles Bibliográficos
Autores principales: English, Diana P, Bellone, Stefania, Schwab, Carlton L, Bortolomai, Ileana, Bonazzoli, Elena, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Lopez, Salvatore, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Santin, Alessandro D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302675/
https://www.ncbi.nlm.nih.gov/pubmed/24890382
http://dx.doi.org/10.1002/cam4.274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302675/
https://www.ncbi.nlm.nih.gov/pubmed/24890382
http://dx.doi.org/10.1002/cam4.274

Ejemplares similares